Paul T. Quinlan, General Counsel at Oruka Therapeutics, Inc. (ORKA), sold 52,000 shares at $106.05 ($5.6M) on 2026-08-14, disclosed to the SEC on 2026-08-14.
Scheduled sale ($5.6M) by General Counsel under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $106.05 | 3,630 | $385K | 6.8% |
| 2 | $107.14 | 10,434 | $1.1M | 19.8% |
| 3 | $107.97 | 14,696 | $1.6M | 28.1% |
| 4 | $109.11 | 10,200 | $1.1M | 19.7% |
| 5 | $110.00 | 9,193 | $1.0M | 17.9% |
| 6 | $111.14 | 3,847 |
| $428K |
| 7.6% |
| Total | $108.49 avg | 52,000 | $5.6M | 100% |
| Filing → |
| ORKA | SELL | 2026-06-15 | $51K | — | Filing → |
| ORKA | SELL | 2026-03-17 | $30K | — | Filing → |
| CBAY | SELL | 2024-01-16 | $236K | — | Filing → |